ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC) Options
In Segment A, individuals will obtain distinct doses and schedules of oral ABBV-744 pill to detect Harmless dosing routine. Further participants will probably be enrolled for the determined monotherapy dosign regimen. In Section B, participants will acquire oral ruxolitinib and ABBV-744 is going to be presented as "include-on" therapy. In Phase C,